GlassScriptPhysician profile
Garrett W Hooker
NPI 1467716480
$1,736.03
in general payments reported to CMS, 2019-2025
27 companies · $594 in 2025
The $594 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.73 · 2020: $226 · 2021: $145 · 2022: $199 · 2023: $293 · 2024: $223 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $287.72 | 2019-2025 | |
| Novo Nordisk INC | $222.44 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $214.43 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $169.37 | 2019-2025 | Tezspire, Repatha, Repatha |
| Abbvie INC. | $157.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $118.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $103.82 | 2022-2025 | Shingrix, Bexsero, Penmenvy |
| Astrazeneca Pharmaceuticals LP | $58.62 | 2023-2025 | Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.86 | 2025 | Caplyta |
| Amarin Pharma, INC. | $50.00 | 2021-2022 | |
| Esperion Therapeutics, INC. | $34.88 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $28.09 | 2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $24.36 | 2025 | |
| Procept Biorobotics Corporation | $21.25 | 2024 | Aquabeam System |
| Biohaven Pharmaceuticals, INC. | $19.67 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $17.76 | 2024 | Inspire |
| Astellas Pharma US INC | $16.79 | 2021 | |
| Merck Sharp & Dohme LLC | $16.60 | 2023 | Verquvo, Belsomra, Lagevrio |
| Eisai INC. | $16.08 | 2021 | |
| Dexcom, INC. | $15.75 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Ascensia Diabetes Care US INC. | $15.15 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.54 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.17 | 2024 | Eliquis |
| Boston Scientific Corporation | $13.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.80 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.62 | 2022 | |
| Phathom Pharmaceuticals, INC. | $8.93 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Hooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.